Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs is a research paper published in Pathogens (2022). On theSindex it has a DataRank of 0. It has been cited 13 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institute of Allergy and Infectious Diseases of the National Institutes of Health
Grant: R01AI025038
National Institute of Allergy and Infectious Diseases of the National Institutes of Health
Grant: #631
National Institute of Allergy and Infectious Diseases of the National Institutes of Health
Grant: #39129
National Institute of Allergy and Infectious Diseases of the National Institutes of Health
Grant: G2018–111
National Institute of Allergy and Infectious Diseases of the National Institutes of Health
Grant: #62966
National Institute of Allergy and Infectious Diseases of the National Institutes of Health
Grant: WT 085879
National Institute of Allergy and Infectious Diseases of the National Institutes of Health
Grant: 108518
A Phase IIa/IIb clinical trial to evaluate the therapeutic efficacy of ChAd63-KH vaccine in patients with persistent post kala-azar dermal leishmaniasis (PKDL).
National Institute of Allergy and Infectious Diseases of the National Institutes of Health
Grant: MR/P022030
Wellcome Trust
Grant: 085879
Therapeutic CD8+ T cell-biased vaccines for human visceral leishmaniasis.
Medical Research Council
Grant: MR/R014973/1
Wellcome Trust
Grant: 108518/Z/15/Z
National Institutes of Health
Grant: 5R01AI025038-03
LEISHMANIA ANTIGEN GENES
FWCI
2.13
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals